XML 50 R34.htm IDEA: XBRL DOCUMENT v3.20.4
Stockholders’ Equity and Stock-Based Compensation (Tables)
12 Months Ended
Dec. 26, 2020
Equity [Abstract]  
Schedule of Non-vested Restricted Stock Activity

Schedule of Non-vested Restricted Stock Activity

   Shares  

Weighted Average Grant Fair Value

 
Outstanding at December 30, 2017   2,629,274   $3.31 
Granted   1,549,000    2.25 
Forfeited   (872,025)   3.78 
Vested   (1,093,000)   3.05 
Outstanding at December 29, 2018   2,213,249    2.51 
Granted   645,000    0.57 
Forfeited   (355,625)   2.95 
Vested   (639,500)   2.98 
Balance at December 28, 2019   1,863,124    1.60 
Granted   2,381,000    1.42 
Forfeited   (153,595)          1.71 
Vested   (1,038,655)   0.96 
Balance at December 26, 2020   3,051,874   $1.67 

Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions

Expected volatility   94.2%
Interest rate   0.2%
Expected life (years)   0.7 
Dividend yield   %

Schedule of Stock-based Compensation Expense

The following table summarizes stock-based compensation expense within each of the categories below as it relates to non-vested restricted common stock awards for the fiscal years 2020, 2019 and 2018 (no tax benefits were recognized):

 

Schedule of Stock-based Compensation Expense 

   2020   2019   2018 
Cost of product revenues  $113,517   $102,629   $418,605 
Research and development   204,599    295,872    725,112 
Selling, general and administrative   503,006    1,658,899    3,647,337 
Total  $821,122   $2,057,400   $4,791,054